Pleural
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy
Immunotherapy 2025 August 20 [Link] Giulia Mazzaschi, Roberto Rosati, Simona D’Agnelli, Roberta Minari, Francesca Trentini, Prisca Tamarozzi, Martina Manini, Martina Zinelli Ronzoni, Alessandra Dodi, Letizia Gnetti, Lorena Bottarelli, Cinzia Azzoni, Gianmarco Martines, Monica Pluchino, Ilaria Toscani, Alessandro Leonetti, Fabiana Perrone, Paola Bordi, Giovanni Bocchialini, Luca Ampollini, Federico Quaini, Marcello Tiseo Abstract Aim: A translational multiscale…
Read MorePemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab
Lung Cancer 2025 September [Link] Sawana Ono, Hirokazu Taniguchi, Koji Kuroda, Teppei Hashimoto, Asuka Okada, Yasuhiro Goto, Hidenori Kitai, Yoichi Nakamura, Shinsuke Ogusu, Tetsunari Hase, Takayo Ota 10, Noriyuki Ebi, Makoto Furugen, Taishi Harada, Yoshiaki Kinoshita, Takaki Mizoguchi, Katsumi Nakatomi, Yoshifumi Soejima, Takahiro Yamada, Shinnosuke Takemoto, Hiroshi Mukae Abstract There is limited evidence regarding the…
Read MoreMolecular expression of glycosaminoglycans modifies the plasticity of biphasic mesothelioma in favor of tumor progression
Glycoconjugate Journal 2025 August 13 [Link] Camila Machado Baldavira, Aline Nery Qualiotto, Tabatha Gutierrez Prieto, Sandra de Morais Fernezlian, Aline Assato, Marcelo Balancin, Teresa Takagaki, Alexandre Ab’Saber, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Vera Luiza Capelozzi Abstract The study aimed to verify whether the expression of glycosaminoglycans (GAGs) and proteoglycans (PGs) in the tumor…
Read MoreA Promising Prognostic Indicator for Pleural Mesothelioma: Pan-Immuno-Inflammation Value
Journal of Clinical Medicine 2025 August 4 [Link] Serkan Yaşar, Feride Yılmaz, Ömer Denizhan Tatar, Hasan Çağrı Yıldırım, Zafer Arık 1, Şuayib Yalçın, Mustafa Erman Abstract Background: Pleural mesothelioma (PM) is a type of cancer that is difficult to diagnose and treat. Patients may have vastly varying prognoses, and prognostic factors may help guide the…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreInhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma
Oncogenesis 2025 August 11 [Link] Yantang Lin, Christelle Dubey, Tereza Losmanova, Samuel Oevgü Yasmin, Jean-Louis Reymond, Ren-Wang Peng, Haibin Deng, Patrick Dorn, Thomas Michael Marti Abstract Pleural mesothelioma (PM) is an aggressive, asbestos-linked cancer with limited treatment options and a poor prognosis. Lactate dehydrogenase B (LDHB) converts lactate to pyruvate, and its silencing reduces mitochondrial…
Read MoreFirst-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study
Lung Cancer 2025 August 5 [Link] Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph 4, Frank Griesinger, Martin Reck, Petra Hoffknecht, Jonas Kuo, Nikolaj Frost, Christian Grohé, Martin Faehling, Jingting Luan, Julia Roeper, Paolo Chesi, Miriam Blasi, Martin Kimmich, Till Olchers, Helge Bischoff, Laura V Klotz, Inn Chung, Petros Christopoulos, Michael Thomas Abstract…
Read MoreSingle-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma
Lung Cancer 2025 August 5 [Link] Ania Alay, Raúl Marín, Elisabet Aliagas, Mireia Gausachs, Max Ruiz-Gil, Ivan Macia, Amaia Ojanguren, Susana Padrones, Eduard Dorca, Jesús Brenes, Ramón Palmero, Víctor Moreno, Holger Heyn, David Cordero, Ernest Nadal, Xavier Solé Abstract Pleural mesothelioma (PM) is a rare and lethal cancer with limited treatment options. Intratumor heterogeneity (ITH)…
Read MoreProspective Analysis of Mesotheliomas in Subjects with BAP1 Cancer Syndrome: Clinical Characteristics and Epigenetic Correlates of Disease
Journal of Thoracic Oncology 2025 August 5 [Link] Xinwei Wu, Frank-Villa Hernandez, Haitao Wang, Ruihong Wang, Stephanie Shiffka, Niharika Shah, Shamus R Carr, Chuong D Hoang, Andrew M Blakely, Alexandra Lebensohn, Keerti Mihsra, Sichuan Xi, Mary R Zhang, Tuana Tolunay, Sudheer Gara, Amanda Absher, Deneise Francis, Amanda Rowland, Maureen Connolly, Stephanie Jacobs, Sandra Orfgen, Kevin…
Read MorePipeline to evaluate YAP-TEAD inhibitors indicates TEAD inhibition represses NF2-mutant mesothelioma
Life Science Alliance 2025 July 31 [Link] Richard Cunningham, Siyang Jia, Krishna Purohit, Michaela Noskova Fairley 1, Marcin K Maniak, Yue Lin, Ning Sze Hui, Rebecca E Graham, Adriano G Rossi, Justyna Cholewa-Waclaw, Pierre O Bagnaninchi, Neil O Carragher, Carsten Gram Hansen Abstract As the core, tumorigenic downstream effectors of the Hippo signalling pathway, YAP/TAZ…
Read More